JP7665047B2 - 免疫賦活化組成物 - Google Patents

免疫賦活化組成物 Download PDF

Info

Publication number
JP7665047B2
JP7665047B2 JP2023564923A JP2023564923A JP7665047B2 JP 7665047 B2 JP7665047 B2 JP 7665047B2 JP 2023564923 A JP2023564923 A JP 2023564923A JP 2023564923 A JP2023564923 A JP 2023564923A JP 7665047 B2 JP7665047 B2 JP 7665047B2
Authority
JP
Japan
Prior art keywords
cells
cd11b
iga
expression
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023564923A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023100745A5 (cg-RX-API-DMAC7.html
JPWO2023100745A1 (cg-RX-API-DMAC7.html
Inventor
礼子 新藏
鵬 高
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JPWO2023100745A1 publication Critical patent/JPWO2023100745A1/ja
Publication of JPWO2023100745A5 publication Critical patent/JPWO2023100745A5/ja
Application granted granted Critical
Publication of JP7665047B2 publication Critical patent/JP7665047B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0216—Bacteriodetes, e.g. Bacteroides, Ornithobacter, Porphyromonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0258—Escherichia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0266—Klebsiella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023564923A 2021-12-02 2022-11-24 免疫賦活化組成物 Active JP7665047B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021196561 2021-12-02
JP2021196561 2021-12-02
PCT/JP2022/043424 WO2023100745A1 (ja) 2021-12-02 2022-11-24 免疫賦活化組成物

Publications (3)

Publication Number Publication Date
JPWO2023100745A1 JPWO2023100745A1 (cg-RX-API-DMAC7.html) 2023-06-08
JPWO2023100745A5 JPWO2023100745A5 (cg-RX-API-DMAC7.html) 2024-05-07
JP7665047B2 true JP7665047B2 (ja) 2025-04-18

Family

ID=86612110

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023564923A Active JP7665047B2 (ja) 2021-12-02 2022-11-24 免疫賦活化組成物

Country Status (7)

Country Link
US (1) US20250127889A1 (cg-RX-API-DMAC7.html)
EP (1) EP4442279A4 (cg-RX-API-DMAC7.html)
JP (1) JP7665047B2 (cg-RX-API-DMAC7.html)
CN (1) CN118613283A (cg-RX-API-DMAC7.html)
CA (1) CA3239834A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330902A (cg-RX-API-DMAC7.html)
WO (1) WO2023100745A1 (cg-RX-API-DMAC7.html)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017178890A (ja) 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
WO2019156251A1 (ja) 2018-02-09 2019-08-15 日東薬品工業株式会社 リポ多糖制御性腸内細菌及びその用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5650780B2 (ja) * 2012-04-04 2015-01-07 日東電工株式会社 ワクチン組成物
CN103961700A (zh) * 2013-02-05 2014-08-06 日东电工株式会社 粘膜给予用疫苗组合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017178890A (ja) 2016-03-31 2017-10-05 富山県 自然免疫を活性化する粘膜ワクチン用アジュバント
WO2018034318A1 (ja) 2016-08-18 2018-02-22 国立大学法人 奈良先端科学技術大学院大学 免疫調節剤
WO2019156251A1 (ja) 2018-02-09 2019-08-15 日東薬品工業株式会社 リポ多糖制御性腸内細菌及びその用途

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
Bratisl Lek Listy，1999年，Vol.100, No.2，pp.92-95
DIAO, Y. et al.，Journal of Medicinal Chemistry，2012年，Vol. 55，pp. 8341-8349
GAO, P., et al.，Integrin CD11b provides a new marker of pre-germinal center IgA+ B cells in murine Peyer’s patches，International Immunology，2021年12月31日，Vol.34, No.5，pp.249-261，https://doi.org/10.1093/intimm/dxab113
International Journal of Immunopharmacology，2000年，Vol.22，pp.843-854
J. Med. Chem.，2018年，Vol.61，pp.2707-2724，DOI: 10.1021/acs.jmedchem.7b01052
JOURNAL OF BIOLOGICAL CHEMISTRY，2006年，Vol.281, No.39，pp.29054-29063
PARK, S., et al.，CD11b regulates antibody class switching via induction of AID，Molecular Immunology，2017年，Vol.87，pp.47-59，http://dx.doi.org/10.1016/j.molimm.2017.04.005
新藏 礼子，腸管における免疫応答の特殊性とその要因 腸管免疫の恒常性における免疫グロブリン遺伝子の体細胞突然変異，臨床免疫・アレルギー科，2012年，Vol.58, No.4，pp.361-367
森田 直樹 ほか，腸管ＩｇＡ抗体による腸内細菌制御，医学のあゆみ，2021年08月28日，Vol.278, No.9，pp.757-760

Also Published As

Publication number Publication date
CN118613283A (zh) 2024-09-06
TW202330902A (zh) 2023-08-01
EP4442279A4 (en) 2025-12-31
JPWO2023100745A1 (cg-RX-API-DMAC7.html) 2023-06-08
CA3239834A1 (en) 2023-06-08
US20250127889A1 (en) 2025-04-24
EP4442279A1 (en) 2024-10-09
WO2023100745A1 (ja) 2023-06-08

Similar Documents

Publication Publication Date Title
Akao et al. Enhancement of antitumor natural killer cell activation by orally administered Spirulina extract in mice
Broom et al. The role of the gut microbiome in shaping the immune system of chickens
López-Santiago et al. Immune response to mucosal Brucella infection
Martirosyan et al. An evolutionary strategy for a stealthy intracellular Brucella pathogen
Hill et al. Intestinal bacteria and the regulation of immune cell homeostasis
JP2022524951A (ja) 腫瘍、腫瘍常在免疫細胞および腫瘍微小環境にコロニー形成するよう操作した免疫刺激性細菌
Meng et al. Methionine enkephalin (MENK) mounts antitumor effect via regulating dendritic cells (DCs)
TW201934139A (zh) 用於治療或預防癌症之組合療法
US11602551B2 (en) Use of inosine for the treatment of t-reg deficiency
EP4442279A1 (en) Immunostimulatory composition
Shah et al. Increased susceptibility to Yersinia enterocolitica Infection of Tff2 deficient mice
Cario Toll-like receptors and gastrointestinal diseases: from bench to bedside?
JP2014095570A (ja) セリアック病に関連する、ＣＤ３００ａ遺伝子欠損マウスおよびＣＤ３００ａ発現細胞の活性調節剤の使用、ならびにＣＤ３００ａ発現細胞の活性調節剤を含有する医薬品
Watts The effect of early microbiome modification on immune development and function in broiler chickens
Pietrasanta PRENATAL ANTIBIOTIC THERAPY PREDISPOSES TO NEONATAL SEPSIS INDUCED BY E. COLI: A ROLE FOR BREAST MILK IGA?
Brisbin et al. Regulation of the intestinal immune system by commensal microbiota in avian and ruminant species.
Pitmon IL-17 and Glucose: Mechanisms of Immunomodulation in the Gut During Intestinal Inflammation and Cancer
US10751398B2 (en) Inflammasome activators and methods of use to treat tumors
WO2025134928A1 (ja) 結腸直腸がんを治療するための組成物
Cedeno Defining the role of the pore-forming apolipoprotein L APOL7C in a Leishmania infection
Krimitza Impact of gut metabolites and antibiotics on immune responses
Russell Intestinal responses to Clostridium perfringens in broilers
Pérez Unraveling the Immunomodulatory Role of 5-Hydroxytryptamine in Pre-weaned Dairy Calves
Regan Identification of novel innate immune mechanisms regulating inflammation in the gastrointestinal tract
WO2005058355A1 (en) Immune stimulation by administration of bacteria

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240301

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240301

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240301

AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20240319

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240329

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240703

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250408

R150 Certificate of patent or registration of utility model

Ref document number: 7665047

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150